Approach to the adolescent requesting contraception

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 1, 2012, Pages 9-15

  Gordon, Catherine M ^a   Pitts, Sarah A B ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DESOGESTREL; GESTAGEN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; NORGESTREL; ORAL CONTRACEPTIVE AGENT;

ACNE; ADOLESCENT HEALTH; ARTICLE; BONE MASS; CONTRACEPTION; DRUG CONTRAINDICATION; DRUG RESPONSE; FRACTURE; HIRSUTISM; HUMAN; INTERPERSONAL COMMUNICATION; MENSTRUAL IRREGULARITY; MIGRAINE AURA; MIGRAINE WITH AURA; OSTEOLYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SIDE EFFECT; THROMBOEMBOLISM; THROMBOPHILIA; WEIGHT GAIN;

ADOLESCENT; ADOLESCENT BEHAVIOR; CONTRACEPTION; CONTRACEPTIVES, ORAL, HORMONAL; COUNSELING; FAMILY PLANNING SERVICES; FEMALE; HEALTH SERVICES ACCESSIBILITY; HUMANS; PREGNANCY; PREGNANCY IN ADOLESCENCE; SEX EDUCATION;

EID: 84855514875     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-1780     Document Type: Article

References (39)

1. Ventura SJ, Abma JC, Mosher WD, Henshaw SK 2009 Estimated pregnancy rates for the United States, 1990-2005: an update. Natl Vital Stat Rep 58:1-14
2. Junkins-Hopkins JM 2010 Hormone therapy for acne. J Am Acad Dermatol 62:486-488
3. 2010 U.S. medical eligibility criteria for contraceptive use, 2010. MMWR Recomm Rep 59:1-86
4. World Health Organization 2009 Medical eligibility criteria for contraceptive use. 4th ed. Geneva: World Health Organization; 1-130
5. Loder EW, Buse DC, Golub JR 2005 Headache and combination estrogen-progestin oral contraceptives: integrating evidence, guidelines, and clinical practice. Headache 45:224-231 (Pubitemid 40393212)
6. Etminan M, Takkouche B, Isorna FC, Samii A 2005 Risk of ischaemic stroke in people with migraine: systematic review and meta-analysis of observational studies. BMJ 330:63
7. Evans RW, Becker WJ 2006 Migraine and oral contraceptives. Headache 46:328-331
8. Feske SK 2007 Stroke in pregnancy. Semin Neurol 27:442-452 (Pubitemid 350022488)
9. Conard J 1999 Biological coagulation findings in third-generation oral contraceptives. Hum Reprod Update 5:672-680 (Pubitemid 30034890)
10. Oger E, Alhenc-Gelas M, Lacut K, Blouch MT, Roudaut N, Kerlan V, Collet M, Abgrall JF, Aiach M, Scarabin PY, Mottier D 2003 Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial. Arterioscler Thromb Vasc Biol 23:1671-1676 (Pubitemid 37108215)
11. Deguchi H, Bouma BN, Middeldorp S, Lee YM, Griffin JH 2005 Decreased plasma sensitivity to activated protein C by oral contraceptives is associated with decreases in plasma glucosylceramide. J Thromb Haemost 3:935-938 (Pubitemid 41632822)
12. Vandenbroucke JP, Rosing J, Bloemenkamp KW, Middeldorp S, Helmerhorst FM, Bouma BN, Rosendaal FR 2001 Oral contraceptives and the risk of venous thrombosis. N Engl J Med 344:1527-1535 (Pubitemid 32429213)
13. Trenor 3rd CC, Chung RJ, Michelson AD, Neufeld EJ, Gordon CM, Laufer MR, Emans SJ 2011 Hormonal contraception and thrombotic risk: a multidisciplinary approach. Pediatrics 127:347-357
14. Poulter NR, Chang CL, Farley TM, Melrik O 1999 Risk of cardiovascular diseases associated with oral progestagen preparations with therapeutic indications. Lancet 354:1610 (Pubitemid 29515956)
15. Vasilakis C, Jick H, del Mar Melero-Montes M 1999 Risk of idiopathic venous thromboembolism in users of progestagens alone. Lancet 354:1610-1611 (Pubitemid 29515957)
16. Zieman M, Hatcher R, Cwiak C, Darney P, Creinin M, Stosur H 2010 A pocket guide to managing contraception. Tiger, GA: Bridging the Gap Foundation
17. Gallo MF, Lopez LM, Grimes DA, Schulz KF, Helmerhorst FM 2006 Combination contraceptives: effects on weight. Cochrane Database Syst Rev 1:CD003987
18. Bonny AE, Ziegler J, Harvey R, Debanne SM, Secic M, Cromer BA 2006 Weight gain in obese and nonobese adolescent girls initiating depot medroxyprogesterone, oral contraceptive pills, or no hormonal contraceptive method. Arch Pediatr AdolescMed160:40-45 (Pubitemid 43042133)
19. Verhaeghe J 2010 Hormonal contraception in women with the metabolic syndrome: a narrative review. Eur J Contracept Reprod Health Care 15:305-313
20. Ozdemir S, Görkemli H, Gezginç K, Ozdemir M, Kiyici A 2008 Clinical and metabolic effects of medroxyprogesterone acetate and ethinyl estradiol plus drospirenone in women with polycystic ovary syndrome. Int J Gynaecol Obstet 103:44-49
21. Africander D, Verhoog N, Hapgood JP 2011 Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception. Steroids 76:636-652
22. Berenson AB, Odom SD, Breitkopf CR, Rahman M 2008 Physiologic and psychologic symptoms associated with use of injectable contraception and 20 microg oral contraceptive pills. Am J Obstet Gynecol 199:351.e1-e12
23. Harel Z, Gold M, Cromer B, Bruner A, Stager M, Bachrach L, Wolter K, Reid C, Hertweck P, Nelson A, Nelson D, Coupey S, Johnson C, Burkman R, Bone H 2007 Bone mineral density in postmenarchal adolescent girls in the United States: associated biopsychosocial variables and bone turnover markers. J Adolesc Health 40:44-53 (Pubitemid 44918376)
24. Ward KA, Adams JE, Roberts SA, Mughal Z, Seif MW 2009 Postpartum bone status in teenage mothers assessed using peripheral quantitative computed tomography. J Clin Densitom 12:219-223
25. Sowers MF, Scholl T, Harris L, Jannausch M 2000 Bone loss in adolescent and adult pregnant women. Obstet Gynecol 96:189-193 (Pubitemid 30447337)
26. Harel Z, Johnson CC, Gold MA, Cromer B, Peterson E, Burkman R, Stager M, Brown R, Bruner A, Coupey S, Hertweck P, Bone H, Wolter K, Nelson A, Marshall S, Bachrach LK 2010 Recovery of bone mineral density in adolescents following the use of depot medroxyprogesterone acetate contraceptive injections. Contraception 81:281-291
27. Cromer BA, Stager M, Bonny A, Lazebnik R, Rome E, Ziegler J, Debanne SM 2004 Depot medroxyprogesterone acetate, oral contraceptives and bone mineral density in a cohort of adolescent girls. J Adolesc Health 35:434-441 (Pubitemid 39576013)
28. Scholes D, LaCroix AZ, Ichikawa LE, Barlow WE, Ott SM 2005 Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception. Arch Pediatr Adolesc Med 159:139-144 (Pubitemid 40194179)
29. Sarfati J, de Vernejoul MC 2009 Impact of combined and progestogen-only contraceptives on bone mineral density. Joint Bone Spine 76:134-138
30. Dorale A, Pitts S, Feldman H, Gordon C, Depot medroxyprogesterone acetate (DMPA) and bone density in adolescents and young adults: a retrospective review. Pediatric Academic Societies and Asian Society for Pediatric Research, 2011 Joint Meeting, Denver, Colorado, 2011 (Abstract)
31. Vestergaard P, Rejnmark L, Mosekilde L 2008 The effects of depot medroxyprogesterone acetate and intrauterine device use on fracture risk in Danish women. Contraception 78:459-464
32. Meier C, Brauchli YB, Jick SS, Kraenzlin ME, Meier CR 2010 Use of depot medroxyprogesterone acetate and fracture risk. J Clin Endocrinol Metab 95:4909-4916
33. Zemel B, Bass S, Binkley T, Ducher G, Macdonald H, McKay H, Moyer-Mileur L, Shepherd J, Specker B, Ward K, Hans D 2008 Peripheral quantitative computed tomography in children and adolescents: the 2007 ISCD Pediatric Official Positions. J Clin Densitom 11:59-74 (Pubitemid 351602188)
34. d'Arcangues C 2006 WHO statement on hormonal contraception and bone health. Contraception 73:443-444
35. Hartard M, Kleinmond C, Wiseman M, Weissenbacher ER, Felsenberg D, Erben RG 2007 Detrimental effect of oral contraceptives on parameters of bone mass and geometry in a cohort of 248 young women. Bone 40:444-450 (Pubitemid 46075201)
36. Hartard M, Kleinmond C, Luppa P, Zelger O, Egger K, Wiseman M, Weissenbacher ER, Felsenberg D, Erben RG 2006 Comparison of the skeletal effects of the progestogens desogestrel and levonorgestrel in oral contraceptive preparations in young women: controlled, open, partly randomized investigation over 13 cycles. Contraception 74:367-375 (Pubitemid 44550041)
37. Tolaymat LL, Kaunitz AM 2009 Use of hormonal contraception in adolescents: skeletal health issues. Curr Opin Obstet Gynecol 21: 396-401
38. Harel Z, Wolter K, Gold MA, Cromer B, Bruner A, Stager M, Bachrach L, Hertweck P, Nelson A, Nelson D, Coupey S, Johnson CC, Burkman R, Bone H 2010 Inadequate vitamin D status in adolescents with substantial bone mineral density loss during the use of depot medroxyprogesterone acetate injectable contraceptive: a pilot study. J Pediatr Adolesc Gynecol 23:209-214
39. Cromer BA, Lazebnik R, Rome E, Stager M, Bonny A, Ziegler J, Debanne SM 2005 Double-blinded randomized controlled trial of estrogen supplementation in adolescent girls who receive depot medroxyprogesterone acetate for contraception. Am J Obstet Gynecol 192:42-47 (Pubitemid 40164218)